CRISPR/Cas9 gene-edited DMD gene modulators (Duke University/Sarepta)

N/A

Report date: 2025/03/19 08:59:15

Base Information

Drug NameCRISPR/Cas9 gene-edited DMD gene modulators (Duke University/Sarepta)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionDystrophin expression stimulantsDMD gene modulators
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDuke University
China Registration ClassN/A

Develop Information

Active CompaniesSarepta Therapeutics IncDuke University
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A